At the news
? BULLISHIMPACT 7/10 6-K filed Apr 27, 2026 at 06:29 ET
AstraZeneca's Saphnelo (anifrolumab) has been approved by the FDA for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), expanding access beyond the current IV infusion. The approval is based on Phase III TULIP-SC trial data showing statistically significant and clinically meaningful reduction in disease activity.
- FDA approved Saphnelo for subcutaneous self-administration using the Saphnelo Pen, a once-weekly autoinjector, for adult SLE patients on standard therapy.
- Approval based on Phase III TULIP-SC trial results demonstrating statistically significant and clinically meaningful reduction in disease activity versus placebo.
- Saphnelo Pen offers patients greater flexibility and convenience compared to the current IV infusion, potentially increasing adoption and market penetration.
- Saphnelo IV is already approved in over 70 countries; subcutaneous formulation previously approved in EU and Japan.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access